title: [Heparin-induced thrombocytopenia Type II (HIT II) A fatal complication of heparin use for thromboembolism prevention].
abstract: Heparin-induced thrombocytopenia type II (HIT II) is the most severe complication during prophylactic treatment with low doses of heparin. Five cases demonstrate the life-threatening consequences of this immune-mediated thromboembolic disease. In order to improve prognosis it is most important to start therapy just before diagnosis is assured by laboratory tests. First choice treatment is the low-molecular-weight heparinoid Orgaran. In patients with an episode of HIT II both low-molecular-weight heparin and unfractionated heparin will be contraindicated for a life time.
authors.affiliation: Institut für Anästhesiologie und operative Intensivmedizin, Diakoniekrankenhaus Rotenburg, Wümme.
authors.forename: G
authors.initials: G
authors.lastname: Hobbensiefken
authors.forename: B
authors.initials: B
authors.lastname: Driller
authors.forename: V
authors.initials: V
authors.lastname: Studtmann
authors.forename: K
authors.initials: K
authors.lastname: Kunz
authors.forename: G
authors.initials: G
authors.lastname: Lehrbach
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D050723:Fractures, Bone / Q000150:complications / Q000628:therapy; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects*; D006622:Hip Prosthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000150:complications; D013923:Thromboembolism / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
chemical_list: D006493:Heparin; D010959:Tissue Plasminogen Activator